[go: up one dir, main page]

SG11201803066VA - Dihydroimidazopyrazinone derivatives useful in the treatment of cancer - Google Patents

Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Info

Publication number
SG11201803066VA
SG11201803066VA SG11201803066VA SG11201803066VA SG11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA SG 11201803066V A SG11201803066V A SG 11201803066VA
Authority
SG
Singapore
Prior art keywords
cancer
treatment
derivatives useful
dihydroimidazopyrazinone
dihydroimidazopyrazinone derivatives
Prior art date
Application number
SG11201803066VA
Other languages
English (en)
Inventor
Richard Ward
Clifford Jones
Steven Swallow
Mark Graham
Andrew Dobson
James Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201803066VA publication Critical patent/SG11201803066VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201803066VA 2015-11-09 2016-11-08 Dihydroimidazopyrazinone derivatives useful in the treatment of cancer SG11201803066VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252726P 2015-11-09 2015-11-09
US201662401351P 2016-09-29 2016-09-29
PCT/EP2016/076932 WO2017080979A1 (fr) 2015-11-09 2016-11-08 Dérivés de dihydroimidazopyrazinone utiles dans le traitement du cancer

Publications (1)

Publication Number Publication Date
SG11201803066VA true SG11201803066VA (en) 2018-05-30

Family

ID=57241113

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201803066VA SG11201803066VA (en) 2015-11-09 2016-11-08 Dihydroimidazopyrazinone derivatives useful in the treatment of cancer

Country Status (35)

Country Link
US (2) US9902731B2 (fr)
EP (1) EP3374359B1 (fr)
JP (1) JP6877423B2 (fr)
KR (1) KR20180074788A (fr)
CN (1) CN108349983B (fr)
AU (1) AU2016351813B2 (fr)
BR (1) BR112018008397B1 (fr)
CA (1) CA3003549A1 (fr)
CL (1) CL2018001226A1 (fr)
CO (1) CO2018004857A2 (fr)
CR (1) CR20180316A (fr)
CY (1) CY1123627T1 (fr)
DK (1) DK3374359T3 (fr)
EA (1) EA038028B1 (fr)
ES (1) ES2780650T3 (fr)
HR (1) HRP20200342T1 (fr)
IL (1) IL258953A (fr)
LT (1) LT3374359T (fr)
ME (1) ME03770B (fr)
MX (1) MX376639B (fr)
MY (1) MY197626A (fr)
NI (1) NI201800058A (fr)
PE (1) PE20181288A1 (fr)
PH (1) PH12018500987A1 (fr)
PL (1) PL3374359T3 (fr)
PT (1) PT3374359T (fr)
RS (1) RS60155B1 (fr)
SG (1) SG11201803066VA (fr)
SI (1) SI3374359T1 (fr)
SM (1) SMT202000152T1 (fr)
SV (1) SV2018005687A (fr)
TN (1) TN2018000119A1 (fr)
TW (1) TWI730012B (fr)
WO (1) WO2017080979A1 (fr)
ZA (1) ZA201803742B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912959QA (en) 2015-10-21 2020-02-27 Otsuka Pharma Co Ltd Benzolactam compounds as protein kinase inhibitors
JP6877423B2 (ja) * 2015-11-09 2021-05-26 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ がんの処置において有用なジヒドロイミダゾピラジノン誘導体
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
JP7352981B2 (ja) * 2018-10-10 2023-09-29 深▲チェン▼市塔吉瑞生物医薬有限公司 ジヒドロイミダゾピラジノン化合物、該化合物を含む組成物およびその使用
US20220213119A1 (en) 2019-03-28 2022-07-07 Jiangsu Hengrui Medicine Ca, Lid. Thienoheterocyclic derivative, preparation method therefor and medical use thereof
WO2020238776A1 (fr) 2019-05-24 2020-12-03 江苏恒瑞医药股份有限公司 Dérivé bicyclicque condensé substituté, son procédé de préparation et son application en médecine
PE20220376A1 (es) * 2019-06-06 2022-03-16 Hutchison Medipharma Ltd Compuestos triciclicos y su uso
KR20220112764A (ko) * 2019-12-05 2022-08-11 아스트라제네카 아베 화학식 (i)의 제조를 위한 방법 및 중간체
JP7409719B2 (ja) * 2019-12-06 2024-01-09 徳昇済医薬（無錫）有限公司 Ｅｒｋ阻害剤としてのチアゾロラクタム系化合物およびその使用
AU2021354821A1 (en) 2020-09-29 2023-06-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal form of pyrrolo heterocyclic derivative and preparation method therefor
CN117529321A (zh) * 2021-06-18 2024-02-06 上海德琪医药科技有限公司 Erk抑制剂和kras抑制剂的组合及其用途
WO2022268065A1 (fr) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Composés en tant qu'inhibiteurs d'erk
US20250281607A1 (en) 2021-07-27 2025-09-11 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2023081860A1 (fr) 2021-11-04 2023-05-11 Skyhawk Therapeutics, Inc. Dérivés d'aminotriazine pour le traitement de la sca3
EP4514806B1 (fr) 2022-04-27 2025-12-17 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
EP4522624A1 (fr) 2022-05-12 2025-03-19 Skyhawk Therapeutics, Inc. Compositions utiles pour moduler l'épissage
WO2024006971A2 (fr) * 2022-07-01 2024-01-04 The Scripps Research Institute Composés antipaludiques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2004041826A1 (fr) * 2002-11-06 2004-05-21 Merck Sharp & Dohme Limited Derives de midazopyrazinones et d'imidazotriazinones utilises comme anxiolytiques agissant via le recepteur gaba-a
GB0520958D0 (en) * 2005-10-14 2005-11-23 Cyclacel Ltd Compound
EP2132178B1 (fr) * 2006-12-20 2015-08-19 Merck Sharp & Dohme Corp. Inhibiteurs de jnk
EP2655376B1 (fr) * 2010-12-22 2017-08-23 Janssen Pharmaceutica NV Dérivés de 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine comme inhibiteurs de la bêta-secrétase (bace)
MA37958B1 (fr) * 2011-10-10 2018-10-31 H Lundbeck As Pde9i ayant un squelette imidazo pyrazinone
JP2013166727A (ja) * 2012-02-16 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ジヒドロイミダゾピラジノン誘導体
DK2820009T3 (en) 2012-03-01 2018-04-16 Array Biopharma Inc Serine / threonine kinase inhibitors
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
MY176049A (en) * 2013-12-06 2020-07-22 Genentech Inc Serine/threonine kinase inhibitors
EP3089788B1 (fr) 2013-12-30 2018-10-24 Genentech, Inc. Inhibiteurs de sérine/thréonine kinases
EP3089980B1 (fr) 2013-12-30 2018-01-31 Array Biopharma, Inc. Inhibiteurs de sérine/thréonine kinases
JP6723926B2 (ja) 2014-04-09 2020-07-15 ジェネンテック， インコーポレイテッド 医薬の製造方法
US10412619B2 (en) * 2014-11-14 2019-09-10 Qualcomm Incorporated Buffer status report for eDCS
WO2016162325A1 (fr) * 2015-04-07 2016-10-13 Astrazeneca Ab Dérivés de 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2h)-ones substitués utilisés comme inhibiteurs de kinase
US10479791B2 (en) 2015-06-03 2019-11-19 Changzhou Jiekai Pharmatech Co. Ltd Heterocyclic compounds as ERK inhibitors
WO2016192064A1 (fr) 2015-06-03 2016-12-08 Js Innopharm (Shanghai) Ltd. Composés hétérocycliques pour le traitement du psoriasis
JP6877423B2 (ja) * 2015-11-09 2021-05-26 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ がんの処置において有用なジヒドロイミダゾピラジノン誘導体

Also Published As

Publication number Publication date
TW201728586A (zh) 2017-08-16
DK3374359T3 (da) 2020-03-30
NI201800058A (es) 2018-10-18
PL3374359T3 (pl) 2020-06-29
CR20180316A (es) 2018-10-05
RS60155B1 (sr) 2020-05-29
US20180237443A1 (en) 2018-08-23
EA038028B1 (ru) 2021-06-24
IL258953A (en) 2018-06-28
EP3374359A1 (fr) 2018-09-19
JP2019503337A (ja) 2019-02-07
US10202391B2 (en) 2019-02-12
BR112018008397B1 (pt) 2023-12-12
ME03770B (fr) 2021-04-20
MX376639B (es) 2025-03-07
CN108349983B (zh) 2021-02-26
SMT202000152T1 (it) 2020-05-08
LT3374359T (lt) 2020-03-25
CA3003549A1 (fr) 2017-05-18
SV2018005687A (es) 2018-07-20
HRP20200342T1 (hr) 2020-06-12
MX2018005725A (es) 2018-08-14
HK1256283A1 (en) 2019-09-20
CL2018001226A1 (es) 2018-10-05
EA201891063A1 (ru) 2018-12-28
US9902731B2 (en) 2018-02-27
PT3374359T (pt) 2020-03-27
TWI730012B (zh) 2021-06-11
CN108349983A (zh) 2018-07-31
CO2018004857A2 (es) 2018-07-19
ZA201803742B (en) 2020-08-26
JP6877423B2 (ja) 2021-05-26
KR20180074788A (ko) 2018-07-03
TN2018000119A1 (en) 2019-10-04
US20170204100A1 (en) 2017-07-20
PE20181288A1 (es) 2018-08-07
AU2016351813B2 (en) 2019-05-30
PH12018500987A1 (en) 2019-01-28
ES2780650T3 (es) 2020-08-26
SI3374359T1 (sl) 2020-04-30
WO2017080979A1 (fr) 2017-05-18
EP3374359B1 (fr) 2020-01-08
CY1123627T1 (el) 2022-03-24
AU2016351813A1 (en) 2018-06-21
MY197626A (en) 2023-06-29
BR112018008397A2 (pt) 2018-10-23

Similar Documents

Publication Publication Date Title
ZA201803742B (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
IL276733A (en) Use of Aribolin in cancer treatment
IL259996A (en) Combinations for cancer treatment
ZA201807810B (en) Adenosine derivatives for use in the treatment of cancer
SMT202100115T1 (it) Combinazioni di inibitori di fgfr e cmet per il trattamento del cancro
HUE044862T2 (hu) IGF-1R ellenanyag-drog konjugátum és alkalmazása rák kezelésében
IL251905B (en) Epilimod for use in the treatment of kidney cancer
IL248767B (en) Trimethoxyphenyl-benzaimidazole compounds for cancer treatment
IL251903B (en) Epilimod for use in the treatment of colon cancer
ZA201707024B (en) Cancer treatment composition
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
IL262143A (en) Improvements in cancer treatment
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL260814A (en) Cancer treatment
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
IL269121A (en) Usl-311 for use in the treatment of cancer
GB201522433D0 (en) Cancer treatment
IL252493B (en) Compounds for use in the prevention or treatment of cancer
GB201410695D0 (en) Uses of oligouronates in cancer treatment
HK1197910B (en) Substituted pyridine derivatives useful in the treatment of cancer
HK1197910A (en) Substituted pyridine derivatives useful in the treatment of cancer